Pierre DAUMAR

Dr. Pierre DAUMAR

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
SRSamuel L. Rice
Samuel L. Rice
CRCeleste A. Roney
Celeste A. Roney
PDPierre DAUMAR
Pierre DAUMAR
JLJason S. Lewis
Jason S. Lewis

30 July 2012 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
PDPierre DAUMAR
Pierre DAUMAR
CWCindy A. Wanger-Baumann
Cindy A. Wanger-Baumann
NPNagavarakishore Pillarsetty
Nagavarakishore Pillarsetty
LFLaura Fabrizio
Laura Fabrizio
SCSean D. Carlin
Sean D. Carlin
JLJason S. Lewis
Jason S. Lewis

24 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
CDClémence Dubois
Clémence Dubois
RDRobin Dufour
Robin Dufour
PDPierre DAUMAR
Pierre DAUMAR
CACorinne Aubel
Corinne Aubel
CSClaire Szczepaniak
Claire Szczepaniak
MBMahchid BAMDAD
Mahchid BAMDAD
Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines

3 August 2015 in Scientific Reports
Verified
Journal Article
Open access
RDRobin Dufour
Robin Dufour
PDPierre DAUMAR
Pierre DAUMAR
EMEmmanuelle Mounetou
Emmanuelle Mounetou
CACorinne Aubel
Corinne Aubel
FKFabrice Kwiatkowski
Fabrice Kwiatkowski
MBMahchid BAMDAD
Mahchid BAMDAD
The triple negative basal-like (TNBL) breast carcinoma is an aggressive and unfavorable prognosis disease. Inhibitors of poly(ADP-ribose) polymerase such as Olaparib could represent a promising targeted therapy but their sensitivity against Multidrug Resistance proteins (MDR), which causes resistance, is not well defined. Thus, our work focused on the analysis of P-gp and BCRP coexpression in the SUM1315 TNBL human cell line, in correlation with Olaparib intracellular concentration. Western blot analyses showed a clear coexpression of P-gp and BCRP in SUM1315 cells. A low cytotoxic Olaparib treatment clearly led to an increased expression of both BCRP and P-gp in these cells. Indeed, after 1.5 h of treatment, BCRP expression was increased with a 1.8 fold increase rate. Then, P-gp took over from 3 h to 15 h with an average increase rate of 1.8 fold and finally returned to control value at 24 h. HPLC-UV analyses showed that, in the same treatment conditions, the intracellular Olaparib concentration increased from 1 h to 3 h and remained relatively stable until 24 h. Results suggest that the resistance mechanism induced by Olaparib in TNBL SUM1315 cell line may be overpassed if a cytotoxic and stable intracellular level of the drug can be maintained.

1 April 2018 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
PDPierre DAUMAR
Pierre DAUMAR
RDRobin Dufour
Robin Dufour
CDClémence Dubois
Clémence Dubois
FPFrédérique Penault-Llorca
Frédérique Penault-Llorca
MBMahchid BAMDAD
Mahchid BAMDAD
EMEmmanuelle Mounetou
Emmanuelle Mounetou

1 July 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PDPierre DAUMAR
Pierre DAUMAR
CDCaroline Decombat
Caroline Decombat
JCJean-Michel Chezal
Jean-Michel Chezal
EDEric Debiton
Eric Debiton
MMMichel Madesclaire
Michel Madesclaire
MGMarie-Josèphe Galmier
Marie-Josèphe Galmier